268 related articles for article (PubMed ID: 23188619)
1. What do we do with chronic lymphocytic leukemia with 17p deletion?
Sellner L; Denzinger S; Dietrich S; Glimm H; Merkel O; Dreger P; Zenz T
Curr Hematol Malig Rep; 2013 Mar; 8(1):81-90. PubMed ID: 23188619
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
Sivina M; Kim E; Wierda WG; Ferrajoli A; Jain N; Thompson P; Kantarjian H; Keating M; Burger JA
Blood; 2021 Dec; 138(24):2589-2592. PubMed ID: 34521099
[No Abstract] [Full Text] [Related]
4. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
6. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
7. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia
Davids MS; Kim HT; Yu L; De Maeyer G; McDonough M; Vartanov AR; Langey R; Fernandes SM; Hellman JM; Francoeur K; Arnason J; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR
Leuk Lymphoma; 2019 May; 60(5):1312-1315. PubMed ID: 30322319
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
10. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
11. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
12. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
[TBL] [Abstract][Full Text] [Related]
13. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.
Schnaiter A; Stilgenbauer S
Hematol Oncol Clin North Am; 2013 Apr; 27(2):289-301. PubMed ID: 23561474
[TBL] [Abstract][Full Text] [Related]
14. What is the best frontline therapy for patients with CLL and 17p deletion?
Badoux XC; Keating MJ; Wierda WG
Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
[TBL] [Abstract][Full Text] [Related]
15. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
17. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
18. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
[TBL] [Abstract][Full Text] [Related]
19.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
20. Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
Milne K; Sturrock B; Chevassut T
Curr Oncol Rep; 2020 Mar; 22(4):36. PubMed ID: 32172299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
